Trial of Apremilast for Oral Ulcers in Behçet’s Syndrome

In a phase 3 trial involving patients with Behçet’s syndrome, the small-molecule phosphodiesterase 4 inhibitor apremilast reduced the number of oral ulcers and pain of ulcers and improved quality-of-life measures as compared with placebo over 12 weeks. Adverse events included diarrhea, nausea, and h...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 381; no. 20; pp. 1918 - 1928
Main Authors Hatemi, Gülen, Mahr, Alfred, Ishigatsubo, Yoshiaki, Song, Yeong-Wook, Takeno, Mitsuhiro, Kim, Doyoung, Melikoğlu, Melike, Cheng, Sue, McCue, Shannon, Paris, Maria, Chen, Mindy, Yazici, Yusuf
Format Journal Article
LanguageEnglish
Published Boston Massachusetts Medical Society 14.11.2019
Subjects
Arthritis
Cosmetics industry
Cytokines
Diarrhea
Drug dosages
Entrepreneurs
Headache
Nausea
Nervous system
Oral administration
Pain
Phosphodiesterase
Phosphodiesterase IV
Quality of life
Ulcers
Vein & artery diseases
Istanbul Turkey
Turkey
Online AccessGet full text

Cover

More Information
Summary:In a phase 3 trial involving patients with Behçet’s syndrome, the small-molecule phosphodiesterase 4 inhibitor apremilast reduced the number of oral ulcers and pain of ulcers and improved quality-of-life measures as compared with placebo over 12 weeks. Adverse events included diarrhea, nausea, and headache.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa1816594